Skip to main content
OpenTrials
Completed

NCT Number: NCT02159157

A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer

This study is designed to randomly assign breast cancer patients requiring and agreeing to chemotherapy into two groups. One group will be receive an exercise prescription aimed at increasing physical activity by a minimum of 10 MET (metabolic equivalent task) hours per week. The other group will not receive a exercise prescription but their activity will be recorded. The hypothesis is that participants that are most active will exhibit improved chemotherapy completion rates, improved fitness, less fatigue and lower levels of markers for inflammation in their blood.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States

About this study

This is a prospective, randomized, single institution feasibility trial. The efficacy of an exercise intervention during chemotherapy for sedentary breast cancer patients will be tested. The investigators goal is to recruit 120 women and men. Assuming 20% attrition rate, 96 will be randomized to two arms, comparing patients assigned to a physical activity program plus general health education materials versus patients assigned to receive standard general health education materials only. Study measures will be obtained before intervention, at 24 weeks, and at the end of the intervention, approximately week 32.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women or men with histologically confirmed breast cancer and no evidence of metastatic disease with a recommendation to begin chemotherapy within 4 weeks.
  • Patients must have recovered from prior surgery.
  • Patients must be able to walk unassisted without oxygen
  • Patients must complete the Physical Activity Readiness questionnaire with "No" answers to all questions; if patient responds with YES answers, OR IS OVER AGE 69, approval must be obtained from the patient's Primary care physician or treating medical oncologist to participate in the study.
  • Able to fast for 12 hours for blood work and Basal Metabolic Rate measurement.
  • Karnofsky performance status > or = to 80%.
  • Previous or ongoing Physical therapy treatments are acceptable.
  • Participants may be enrolled on other treatment-based clinical trials but may not be enrolled on any other weight loss trials.
  • Participants must have a baseline activity level of < 150 minutes/wk of moderate to vigorous activity as calculated using the moderate to vigorous components of the LTEQ (leisure time exercise questionnaire) for physical activity (completed during screening).

Exclusion criteria

  • Patients less than 18 years of age.
  • Patients with history of acute MI (myocardial infarction) or CVA (cerebral vascular accident) within the last 12 months.
  • Patients who are oxygen dependent.
  • Patients unable to give informed consent indicating they are aware of the investigational nature of this intervention prior to entry into the study.
  • Patients with a Karnofsky performance status of < 80%.
  • Pregnant.
  • Unable to read or write in English.

Treatment and study plan

Exercise Prescription

Behavioral

A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.

Primary outcomes

  1. Change in activity as measured by the Activity Log

    Time frame: from baseline to week 32

    A log will be used to record patient's exercise activity and pedometer data on a weekly and monthly basis.

Secondary outcomes

  1. Received Dose Intensity of chemotherapy (RDI)

    Time frame: 32 weeks

    The RDI is calculated by (delivered dose)/(standard dose) x 100. Delivered dose = (actual total dose in mg/m2)/ (total days required to complete the treatment) Standard dose = (recommended total dose) / (total days planned to complete the treatment)

  2. Change from baseline (day -28 to day 1) fatigue as measured by FACIT-F

    Time frame: baseline (Day -28 to 1), week 24, 32 weeks

    Fatigue as measured by the FACIT-F survey

  3. Change from baseline (day -28 to 1) Absolute neutrophil count and hemoglobin

    Time frame: baseline (Day -28 to 1), 32 weeks

  4. Change from Baseline (day -28 to day 1) C-reactive protein

    Time frame: Baseline (day -28 to day 1) and week 32

    levels of C- reactive protein

  5. Change from Baseline (Day -28 to day 1) Fasting insulin

    Time frame: Baseline (day -28 to day 1) and week 32

    Fasting insulin levels measured in blood at baseline (day -28 to day 1) and week 32

  6. Change from Baseline (day -28 to day 1) of Resting metabolic rate (calculated by Respiratory quotient/ resting energy expenditure measured in kcal/day)

    Time frame: baseline (day -28 to day 1) and week 32

  7. Change in Body composition as indicated by % of total body fat, bone density (g/cm2), and T score

    Time frame: baseline (day -28 to day 1) and week 32

  8. Change in Resting heart rate from baseline (day -28 to day 1)

    Time frame: baseline (day -28 to day 1) and week 32

  9. Change in Waist-hip ratio from baseline (day -28 to day 1)

    Time frame: baseline (day -28 to day 1) and week 32

  10. Change in steps recorded from baseline (day -28 to day 1) as measure by Pedometer data

    Time frame: weekly for 32 weeks

    Average steps per week for weeks 1-32

  11. Measures how likely a person is to continue with exercise prescription.

    Time frame: From baseline to Week 32

    How the participant is feeling about the exercise.

Sponsors and collaborators

Lead sponsor

Dartmouth-Hitchcock Medical Center

Other

Registry information

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Jun 9, 2014
Registry last updated
Aug 21, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.